US Patent Issued to The General Hospital, Massachusetts Institute of Technology, Beth Israel Deaconess Medical Center on Aug. 26 for "Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,396,996, issued on Aug. 26, was assigned to The General Hospital Corp. (Boston), Massachusetts Institute of Technology (Cambridge, Mass.) and Beth Israel Deaconess Medical Center Inc. (Boston).

"Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance" was invented by Mo Motamedi (Boston), Junichi Hanai (Boston), Vikas Sukhatme (Boston) and Mohammad Movassaghi (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are compounds, pharmaceutical compositions, and methods for use in reversing cancer chemoresistance."

The patent was filed on Aug. 6, 2020, under Application No. 17/632,54...